---

Cardiovascular diseases result in millions of deaths worldwide, many of which could have been avoided if identified at an early stage. Therefore, detection of cardiovascular biomarkers (cardiac troponin, cTnI, being the main target), plays a vital role by reducing the critical fatality rate and taking timely adequate precautions. 

While cTnI quantification has been described in many reports, highly sensitive point-of-care testing (POCT) is the next challenge for the detection of cardiac biomarkers. Field effect transistors represent, in this context, an interesting class of devices with many advantages such as high sensitivity, cost-effectiveness, miniaturization... We have recently demonstrated the validity and sensitivity of a graphene-based field-effect transistor as a POCT option for the rapid and highly sensitive detection of cTnI, allowing the quantification of the cardiac biomarker cTnI in patient blood samples with very low or even undetectable levels with currently used clinical bioassays. Our goal is to refine cardiovascular risk stratification in patients with cardiovascular risk factors such as smoking, type 2 diabetes, dyslipidemia and obesity, and thus improve the adaptation of preventive measures and medications in a personalized manner.

Highly performing graphene-based field effect transistor for the differentiation between mild-moderate-severe myocardial injury
By: Rodrigues, T (Rodrigues, Teresa) ; Mishyn, V (Mishyn, Vladyslav) ; Leroux, YR (Leroux, Yann R.) ; Butruille, L (Butruille, Laura) ; Woitrain, E (Woitrain, Eloise) ; Barras, A (Barras, Alexandre) ; Aspermair, P (Aspermair, Patrik) ; Happy, H (Happy, Henri) ; Kleber, C (Kleber, Christoph) ; Boukherroub, R (Boukherroub, Rabah) ; Montaigne, D (Montaigne, David) ; Knoll, W (Knoll, Wolfgang) ; Szunerits, S (Szunerits, Sabine).
http://dx.doi.org/10.1016/j.nantod.2022.101391